EVIDENCE BOARD / 02
Sermorelin research, laid out as a forensic record
What the controlled studies established, what the anti-doping labs can detect, and where the adult data run out — each cell tied to its source.
Start here
This page sorts the sermorelin research into three registers: what the literature genuinely shows, what can now be detected, and what is still missing. The confirmed endocrine results are real and measured — growth hormone and IGF-1 rose in controlled studies, and in older men two weeks of GHRH(1-29) restored those values toward young-adult levels [2]. The detection story is the newer chapter: anti-doping laboratories have built validated urine tests that confirm sermorelin and its relatives below one nanogram per milliliter [9][13]. And the gaps are stated plainly — rigorous long-term adult and weight-loss data do not yet exist [5]. Numbers below are what was administered to which species in which study; none is a dosing instruction.
What the controlled endocrine studies established
In healthy older men (mean 68 years), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour growth hormone and IGF-1; after the high dose, GH/IGF-1 parameters no longer differed from those of young men, with no effect on fasting glucose [2]. This is the cornerstone adult finding: a short course moved an aging endocrine axis back toward a younger profile, through the body's own pulsatile secretion.
In prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth — first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year — without excessive IGF-1 generation [1]. In 30 healthy men, intravenous GHRH(1-29)NH2 elicited significant growth-hormone release at doses as low as 0.25 mcg/kg, with maximal release at 1-2 mcg/kg [3]. These are the rectangular, reproducible results the GHRH(1-29) literature is built on.
Sermorelin benefits
What benefits has sermorelin research examined?
The benefits sermorelin research has actually examined cluster on the GH/IGF-1 axis: restored growth hormone and IGF-1 in older men [2], accelerated growth in GH-deficient children [1], and — across the broader GHRH-analog class — a cognition signal. In a randomized, placebo-controlled trial, 20 weeks of a GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable effect on cognition in older adults with and without mild cognitive impairment, raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% [6]. That is drug-class GHRH evidence, not a sermorelin-specific outcome — a distinction the anti-aging-outpaces-evidence caveat exists to protect [5].
Sermorelin before and after: what controlled studies report
"Sermorelin before and after" is best read as before-and-after laboratory values, not photographs. Before treatment, the older men in the cornerstone study had the blunted growth hormone and IGF-1 typical of aging; after 14 days of high-dose twice-daily GHRH(1-29), those values were statistically indistinguishable from young men's, with fasting glucose unchanged [2]. In GH-deficient children, the before-and-after is a height-velocity curve: ~4.1 cm/year climbing to ~7-8 cm/year in the first year [1].
Body-composition "before and after" claims belong to the class, not the molecule: the tesamorelin trial's measured change was a 7.4% reduction in percent body fat over 20 weeks [6]. Rigorous sermorelin-specific body-composition or weight-loss trials are lacking, so any dramatic transformation marketed for sermorelin alone outpaces the published evidence [5].
Sermorelin side effects reported in studies
Sermorelin side effects reported in studies have generally been mild. In the controlled trials, adverse events were limited and the high-dose older-men study found no effect on fasting glucose [2]; in the GHRH-analog cognition trial, adverse events were described as mild [6]. Injection-site reactions are the most commonly noted effect for a subcutaneous peptide.
The substantive safety consideration is theoretical rather than observed: because growth hormone and IGF-1 are mitogenic, chronically elevating them is theorized to carry oncologic risk — a recognized caution for any GH-axis intervention, even one that works through feedback-regulated pulsatile secretion [5]. Long-term adult tolerability data specifically for anti-aging use remain limited [5], which is the honest counterweight to the benefit findings above.
Anti-doping detection of GHRH analogs
Sermorelin is detectable. Growth-hormone secretagogues, including GHRH and its analogues, appear on the WADA Prohibited List under hormone and metabolic modulators (S2) and are prohibited in sport at all times, and the analytical science to enforce that has matured rapidly. Magnetic-bead immunopurification with optimized surface chemistry enriches GHRH and its analogues — sermorelin, tesamorelin, and CJC-1295 — from human urine before LC-high-resolution mass spectrometry, a validated method with a 0.2 ng/mL limit of detection [9].
A single WADA-validated LC-MS procedure extracts and detects peptidic doping analytes of 2-10 kDa from urine, including the GHRHs sermorelin, CJC-1295, and tesamorelin together with their metabolites [14], and a 2026 nano-LC quadrupole/orbitrap method screens and confirms the same analogues plus the primary sermorelin metabolite to limits of 0.5 ng/mL or lower [13]. Earlier immunoaffinity LC-HRMS/MS work established qualitative identification of GHRHs in plasma [8], and a 2021 review summarizes the detection field as a whole [7].
Sermorelin vs tesamorelin
Sermorelin vs tesamorelin
Sermorelin vs tesamorelin is a native-versus-stabilized comparison within the GHRH-analog family. Sermorelin is the unmodified GHRH(1-29) fragment with a ~10-12 minute plasma half-life [3]; tesamorelin is a stabilized synthetic GHRH analog with a longer duration of action and an FDA approval — for HIV-associated lipodystrophy specifically, not for general anti-aging. Most of the GHRH-analog body-composition and cognition evidence comes from tesamorelin trials (7.4% body-fat reduction; favorable cognition; IGF-1 +117%) [6], which is why this digest attributes those outcomes to the class and to tesamorelin by name, rather than to sermorelin.
How the research community frames sermorelin
Does sermorelin work?
In controlled studies GHRH(1-29) raised growth hormone and IGF-1: it accelerated height velocity in GH-deficient children [1] and, at high dose twice daily for 14 days, restored GH/IGF-1 toward young-adult levels in older men [2]. Anti-aging body-composition claims outpace the long-term evidence [5].
How does sermorelin differ from direct HGH injections?
Sermorelin acts upstream on the pituitary to stimulate the body's own pulsatile growth hormone with feedback intact, whereas recombinant HGH supplies exogenous growth hormone directly; an editorial argued the secretagogue route is the more physiologic approach to adult-onset GH insufficiency [4].
Does sermorelin affect the brain?
GHRH administration has been linked to favorable cognitive effects in controlled trials of older adults and to slow-wave-sleep effects; the strongest cognition data are from the GHRH-analog (tesamorelin) trial [6].